Vaseem Mahboob Sells 26,287 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 26,287 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $25.88, for a total transaction of $680,307.56. Following the completion of the transaction, the chief financial officer directly owned 60,609 shares of the company’s stock, valued at $1,568,560.92. This represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Up 0.4%

Kestra Medical Technologies stock opened at $28.00 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The company’s 50-day moving average is $23.49 and its 200-day moving average is $22.66. The firm has a market capitalization of $1.64 billion, a PE ratio of -11.57 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a fifty-two week low of $15.06 and a fifty-two week high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Trading of Kestra Medical Technologies

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in Kestra Medical Technologies in the 1st quarter valued at $11,036,000. Woodline Partners LP acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth $2,510,000. Jane Street Group LLC bought a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $756,000. Geode Capital Management LLC boosted its position in shares of Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after acquiring an additional 285,579 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in shares of Kestra Medical Technologies in the second quarter valued at about $256,000.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research report on Monday. They set an “overweight” rating and a $30.00 price objective for the company. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.